reports
Straumann Holding AG: 1 director
A director at Straumann Holding AG bought 600 shares at 117.875CHF and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Wolters Kluwer unveils AI center; Provides direct access to its AI-dri...
Wolters Kluwer unveils AI center; Provides direct access to its AI-driven solutions, insights and expertise PRESS RELEASE Wolters Kluwer unveils AI center; Provides direct access to its AI-driven solutions, insights and expertise Alphen aan den Rijn – May 6, 2024 – Wolters Kluwer, a global leader in professional information, software solutions, and services, today unveiled its dedicated . The launch marks the company's ongoing commitment to combining deep domain knowledge with cutting-edge technology such as artificial intelligence (AI), which Wolters Kluwer has been incorporating into ...
AMS AMS AG
APAML APERAM SA
EVT EVOTEC SE
SBS STRATEC SE
ELG ELMOS SEMICONDUCTOR SE
TPE PVA TEPLA AG
BVB BORUSSIA DORTMUND GMBH & CO. KGAA
MBB MBB INDUSTRIES SE
PNL POSTNL NV
SOI SOITEC SA
ASM ASM INTERNATIONAL N.V.
MBWS MARIE BRIZARD WINE & SPIRITS SA
AIXA AIXTRON SE
ECV ENCAVIS AG
PFV PFEIFFER VACUUM TECHNOLOGY AG
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
WAF SILTRONIC AG
MELE MELEXIS NV
TWEKA TKH GROUP N.V. CERT
SMHN SUESS MICROTEC AG
VACN VAT GROUP AG
XFAB X-FAB SILICON FOUNDRIES SE
ASML ASML HOLDING NV
STM STMICROELECTRONICS NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
ALKAL KALRAY SA
JEN JENOPTIK AG
AF AIR FRANCE - KLM
ARM ARM HOLDINGS PLC
AMS AMS AG
APAML APERAM SA
EVT EVOTEC SE
SBS STRATEC SE
ELG ELMOS SEMICONDUCTOR SE
TPE PVA TEPLA AG
BVB BORUSSIA DORTMUND GMBH & CO. KGAA
MBB MBB INDUSTRIES SE
PNL POSTNL NV
SOI SOITEC SA
ASM ASM INTERNATIONAL N.V.
MBWS MARIE BRIZARD WINE & SPIRITS SA
AIXA AIXTRON SE
ECV ENCAVIS AG
PFV PFEIFFER VACUUM TECHNOLOGY AG
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
WAF SILTRONIC AG
MELE MELEXIS NV
TWEKA TKH GROUP N.V. CERT
SMHN SUESS MICROTEC AG
VACN VAT GROUP AG
XFAB X-FAB SILICON FOUNDRIES SE
ASML ASML HOLDING NV
STM STMICROELECTRONICS NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
ALKAL KALRAY SA
JEN JENOPTIK AG
AF AIR FRANCE - KLM
ARM ARM HOLDINGS PLC
- Oliver Metzger
- Stephan Wulf
Evotec SE : Despite strong disappointments we continue to see value, e...
>Guidance came as huge disappointment - The extremely disappointing guidance for FY 2024 and the withdrawal of the mid-term outlook 2025 came as the result of a deteriorating environment in some business areas, limited visibility regarding the success of countermeasures and the change in the CEO, who certainly did not want to be confronted with an overly ambitious guidance. This new situation requires a substantial update of our valuation model, which we only revised ...
- Carole Braudeau
- Carole Braudeau
- Dominic Rose
- Naresh Chouhan
Sanofi - The Path to €120 (BUY, TP EUR120 [110], 7pgs)
This new analysis shows how Sanofi shares get to €120 (+c.30%) by end 2025. We have conducted a foundational analysis that investors can refer to over the next 18mths as Sanofi releases at least 15 P2 & P3 pipeline readouts. We show the upside potential from every single readout and show that just 4 drugs could add €18/share upon successful readouts. In addition to multiple readouts, the likely Consumer Health spin in Q4, the tolebrutinib overhang being resolved one way or another and a strong C...
- Konrad Zomer
- Thomas Zlowodzki
LHA DEUTSCHE LUFTHANSA AG
MT ARCELORMITTAL SA
GALP GALP ENERGIA SGPS SA CLASS B
DBK DEUTSCHE BANK AG
FORTUM FORTUM OYJ
DAI DAIMLER AG
RXL REXEL SA
TEP TELEPERFORMANCE SE
WKL WOLTERS KLUWER NV
REE RED ELECTRICA CORP. SA
ORSTED ORSTED
GN GN STORE NORD A/S
VOW3 VOLKSWAGEN AG PREF
CAP CAPGEMINI SE
NEM NEMETSCHEK SE
RAA RATIONAL AG
AENA AENA SME SA
CABK CAIXABANK SA
WLN WORLDLINE SA
INGA ING GROEP NV
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
STLA STELLANTIS N.V.
SHEL SHELL PLC
GSK GSK PLC
DSFIR KONINKLIJKE DSM N.V.
NOVO B NOVO NORDISK A/S
- Konrad Zomer
- Thomas Zlowodzki
ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 05/02/2024
We are removing GALP from our ODDO BHF European Large Caps list. The stock has chalked up a performance of +31.3% since its inclusion in the list on 20 March. Our analyst is adopting today a Neutral recommendation (vs Outperform) on the stock. - ...
LHA DEUTSCHE LUFTHANSA AG
MT ARCELORMITTAL SA
GALP GALP ENERGIA SGPS SA CLASS B
DBK DEUTSCHE BANK AG
FORTUM FORTUM OYJ
DAI DAIMLER AG
RXL REXEL SA
TEP TELEPERFORMANCE SE
WKL WOLTERS KLUWER NV
REE RED ELECTRICA CORP. SA
ORSTED ORSTED
GN GN STORE NORD A/S
VOW3 VOLKSWAGEN AG PREF
CAP CAPGEMINI SE
NEM NEMETSCHEK SE
RAA RATIONAL AG
AENA AENA SME SA
CABK CAIXABANK SA
WLN WORLDLINE SA
INGA ING GROEP NV
BBVA BANCO BILBAO VIZCAYA ARGENTARIA S.A.
STLA STELLANTIS N.V.
SHEL SHELL PLC
GSK GSK PLC
DSFIR KONINKLIJKE DSM N.V.
NOVO B NOVO NORDISK A/S
- Konrad Zomer
Wolters Kluwer : Q1 trading update confirms the ongoing strong operati...
>Ongoing strong operational performance, both margins and FCF up yoy - With Euronext closed today because of Labour day, there is no rush to absorb the content of Wolters Kluwer’s Q1 trading update. It reads well and reflects an ongoing solid operational performance. Organic revenue growth in Q1 was 6% (FY 2023: 6%) with recurring revenue growth 7%, expert solutions up 8% organically (now 59% of the group) and cloud software revenues up 16% (2023: +15%). In Q1, both t...
Press Release: Beyfortus real-world evidence published in The Lancet s...
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1-6Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the o...
Communiqué de presse : Des données de vie réelle concernant Beyfortus ...
Communiqué de presse : Des données de vie réelle concernant Beyfortus publiées dans The Lancet montrent une réduction de 82 % des hospitalisations de nourrissons dues au VRS Des données de vie réelle concernant Beyfortus publiées dans The Lancet montrent une réduction de 82 % des hospitalisations de nourrissons dues au VRS De nouvelles données de vie réelle montrent que Beyfortus (nirsevimab) a permis de réduire sensiblement les infections des voies respiratoires inférieures dues au VRS chez les nourrissons, de même que les hospitalisations, au cours de la saison virale 2023-2024, compa...
- David Vagman
- CFA
- Marc Hesselink
- CFA
- Thymen Rundberg
Wolters Kluwer/Good start to the year/BUY
Wolters Kluwer reported a 1Q24 trading update slightly ahead of our expectations. Overall organic revenue growth was inline with our estimates, and we see strong performance across the company's largest divisions Health and Tax & Accounting offset slightly lower-than-expected growth in Corporate Performance & ESG. We make minor adjustments to our estimates and keep our BUY and €170 target price.
Sanofi: 1 director
A director at Sanofi bought 1,000 shares at 91.380EUR and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...
- Thomas Couvreur
Wolters Kluwer FIRST LOOK: Solid 1Q24 update; FY24 guidance reiterated
Wolters Kluwer reported a limit trading update highlighting some top line figures. WKL has a good start to the year despite some challenging environments and difficult comparables in some segments. FY24 guidance provided last quarter has been reiterated today. If WKL continues this strong growth trajectory, supported by solid margins, we believe our estimate are likely to end up too conservatively.
Wolters Kluwer First-Quarter 2024 Trading Update
Wolters Kluwer First-Quarter 2024 Trading Update Wolters Kluwer First-Quarter 2024 Trading Update Alphen aan den Rijn, May 1, 2024 – Wolters Kluwer, a global leader in professional information, software solutions and services, today releases its first-quarter 2024 trading update. Highlights Full-year 2024 guidance reiterated.First-quarter revenues up 6% in constant currencies and up 6% organically. Recurring revenues (82%) up 7% organically; non-recurring revenues up 1% organically.Expert solutions revenues (59%) up 8% organically.Cloud software revenues (18%) up 16% organically. ...
EssilorLuxottica: EssilorLuxottica 2024 Annual Shareholders’ Meeting, ...
EssilorLuxottica: EssilorLuxottica 2024 Annual Shareholders’ Meeting, starting a new chapter of the Company’s history EssilorLuxottica 2024 Annual Shareholders’ Meeting,starting a new chapter of the Company’s history All resolutions proposed by the Board of Directors adoptedDividend of Euro 3.95 per share, with option for payment in sharesAll directors re-appointed to the new Board of DirectorsFrancesco Milleri and Paul du Saillant confirmed as Chairman and CEO and Deputy CEO Charenton-le-Pont, France (April 30, 2024 – 6:00 pm CEST) – EssilorLuxottica Annual Shareholders’ Meeting was held...
EssilorLuxottica: Assemblea Annuale degli Azionisti 2024, inizia un nu...
EssilorLuxottica: Assemblea Annuale degli Azionisti 2024, inizia un nuovo capitolo della storia di EssilorLuxottica Assemblea Annuale degli Azionisti 2024,inizia un nuovo capitolo della storia di EssilorLuxottica Approvate tutte le delibere proposte dal Consiglio di AmministrazioneDividendo pari a Euro 3,95 per azione, con opzione per il pagamento in azioniRiconferma di tutti gli attuali Amministratori per il nuovo Consiglio di AmministrazioneFrancesco Milleri e Paul du Saillant confermati nei rispettivi ruoli di Presidente e Amministratore Delegato e Vice Amministratore Delegato Ch...
Press Release: Annual General Meeting of April 30, 2024
Press Release: Annual General Meeting of April 30, 2024 Annual General Meeting of April 30, 2024 Approval of the financial statements for the fiscal year 2023Distribution of a cash dividend of €3.76 per share, with payment as of May 15, 2024Board composition: renewal of two Directors and appointment of three new Independent Directors Paris, April 30, 2024. The Combined General Shareholders’ Meeting of Sanofi was held on April 30, 2024, under the chairmanship of Frédéric Oudéa. All resolutions submitted to the vote were adopted by the shareholders. The General Meeting approved the indi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.